Agios Pharmaceuticals AGIO Operating Lease Liabilities (Total)
Operating Lease Liabilities (Total) at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiability.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's operating lease liabilities (total).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's operating lease liabilities (total)?
- Agios Pharmaceuticals (AGIO) reported operating lease liabilities (total) of $35.75M in Q1 2026.
- How has Agios Pharmaceuticals's operating lease liabilities (total) changed year-over-year?
- Agios Pharmaceuticals's operating lease liabilities (total) decreased by 32.5% year-over-year, from $52.94M to $35.75M.
- What is the long-term trend for Agios Pharmaceuticals's operating lease liabilities (total)?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's operating lease liabilities (total) has grown at a -17.4% compound annual growth rate (CAGR), from $104.55M to $40.21M.
- What does operating lease liabilities (total) mean?
- This represents the total present value of future lease payments for operating leases, recognized as a liability on the balance sheet. It reflects the company's long-term commitment to leased assets such as office space, warehouses, and equipment. Tracking this helps investors evaluate the company's off-balance-sheet financing obligations and overall debt-like commitments.